Marker Therapeutics Non-Current Deferred Revenue (Quarterly) Analysis

Marker Therapeutics, Inc. (MRKR)

1.81 -0.19 (-9.50%) USD | NASDAQ | Jan 12, 11:51

View Non-Current Deferred Revenue (Quarterly) for MRKR.
Upgrade now.

Sep '18

Jan '19

May '19

285.00

270.00

255.00

240.00

View Non-Current Deferred Revenue (Quarterly) Chart

Start Trial

View Historical Data

Start Trial

View Non-Current Deferred Revenue (Quarterly) Range, Past 5 Years

Start Trial

Minimum

Maximum

Average

Median

View Non-Current Deferred Revenue (Quarterly) Benchmarks

Start Trial

ADMA Biologics, Inc.	Upgrade
Viridian Therapeutics, Inc.	Upgrade
Neurocrine Biosciences, Inc.	--
Kiniksa Pharmaceuticals International Plc	Upgrade
AIM ImmunoTech, Inc.	--